Eyestem will be presenting its data at the ARVO 2025 Annual Meeting as well as the 10th Retinal Cell and Gene Therapy ...

ARVO meeting will be held in Salt Lake City, Utah and feature presentation on clinical trials from around the globe.

Eyecyte-RPE™, in patients with geographic atrophy (GA) secondary to dry age-related macular degeneration (AMD). All patients across three cohorts were dosed without any serious adverse events.

Astellas confirmed today that it will withdraw its EMA filing for avacincaptad pegol as a treatment for eye disorder geographic ... secondary to age-related macular degeneration (AMD), a leading ...

Astellas has suffered another major setback with geographic atrophy (GA ... in the US since 2023 for GA secondary to age-related macular degeneration (AMD), a leading cause of blindness, given ...

EYLEA ® (aflibercept) Injection 2 mg is a prescription medicine approved for the treatment of patients with Wet Age-Related Macular Degeneration (AMD), Macular Edema following Retinal Vein Occlusion ...

Annexon achieved primary endpoints in two Phase 3 studies for tanruprubart in treating Guillain-Barre Syndrome, setting the stage for a pre-BLA meeting ...

One of Astellas’ projects is a study looking at a stem-cell-based treatment for geographic atrophy — an advanced form of age-related macular degeneration, which is when the part of retina ...

Avacincaptad pegol and pegcetacoplan have similar 12-month outcomes in slowing GA, with pegcetacoplan requiring fewer injections.